Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -59.22% is 13% above its 5-year average of -67.88%, around the middle of its 5-year range (-113.79%–-13.71%).
23.70% below its 12-month average of -47.88%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -17.31%.
RETURN ON ASSETS (ROA)
-59.22%
RETURN ON ASSETS (ROA) AVG TTM
-47.88%
RETURN ON ASSETS (ROA) AVG 3Y
-51.20%
RETURN ON ASSETS (ROA) AVG 5Y
-67.88%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-23.70%
CURRENT VS 3Y AVG
-15.66%
CURRENT VS 5Y AVG
+12.76%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.37%
median of 781 covered companies
CURRENT VS SECTOR MEDIAN
-88.78%
vs the sector median at left
Aquestive Therapeutics, Inc.
Market Cap
$571.50M
Return on Assets (ROA)
-59.22%
TTM Avg
-47.88%
3Y Avg
-51.20%
5Y Avg
-67.88%
Market Cap
$566.03M
Return on Assets (ROA)
20.70%
TTM Avg
2.32%
3Y Avg
-24.93%
5Y Avg
-30.88%
Market Cap
$562.70M
Return on Assets (ROA)
-20.89%
TTM Avg
7.49%
3Y Avg
-5.84%
5Y Avg
-12.60%
Market Cap
$560.00M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$590.24M
Return on Assets (ROA)
-7.77%
TTM Avg
-7.89%
3Y Avg
-5.07%
5Y Avg
-5.95%
Market Cap
$588.21M
Return on Assets (ROA)
-7.75%
TTM Avg
-4.25%
3Y Avg
-2.93%
5Y Avg
9.76%
Market Cap
$598.37M
Return on Assets (ROA)
45.55%
TTM Avg
3.15%
3Y Avg
-47.64%
5Y Avg
-20.78%
Market Cap
$540.28M
Return on Assets (ROA)
-124.45%
TTM Avg
-92.75%
3Y Avg
-98.77%
5Y Avg
-98.11%
Market Cap
$546.14M
Return on Assets (ROA)
-37.16%
TTM Avg
-32.95%
3Y Avg
-32.95%
5Y Avg
-32.95%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | $571.50M | -59.22% | -47.88% | -51.20% | -67.88% |
| CorMedix Inc. (CRMD)vs › | $566.03M | 20.70% | 2.32% | -24.93% | -30.88% |
| CytomX Therapeutics, Inc. (CTMX)vs › | $562.70M | -20.89% | 7.49% | -5.84% | -12.60% |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| OrthoPediatrics Corp. (KIDS)vs › | $590.24M | -7.77% | -7.89% | -5.07% | -5.95% |
| Fulgent Genetics, Inc. (FLGT)vs › | $588.21M | -7.75% | -4.25% | -2.93% | 9.76% |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $598.37M | 45.55% | 3.15% | -47.64% | -20.78% |
| Nuvectis Pharma, Inc. (NVCT)vs › | $540.28M | -124.45% | -92.75% | -98.77% | -98.11% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $546.14M | -37.16% | -32.95% | -32.95% | -32.95% |
| AngioDynamics, Inc. (ANGO)vs › | $597.05M | -13.75% | -12.94% | -23.44% | -17.36% |
ROA
-59.2%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -52.23% |
| 2024-12-31 | -43.52% |
| 2023-12-31 | -13.71% |
| 2022-12-31 | -95.34% |
| 2021-12-31 | -113.79% |
| 2020-12-31 | -88.71% |
| 2019-12-31 | -84.41% |
| 2018-12-31 | -70.67% |
| 2017-12-31 | -20.74% |
| 2016-12-31 | -24.38% |
